Why These 5 Stocks Are Trending on Tuesday

4. Roivant Sciences Ltd. (NASDAQ:ROIV) has surged 5.62% as of 1:17 PM ET after a subdivision of the company, Dermavant Sciences, got the high-profile approval by the U.S. Food and Drug Administration for its launch of Vtama cream. The cream is designed to treat cases of acute skin-related disorders such as psoriasis. The analysts are bullish on Roivant Sciences Ltd. (NASDAQ:ROIV) stock with a buy rating and an average price target of $14.2. The target price provides a potential upside of nearly 295% from the last closing price.

Overall, 27 hedge funds held a position in Roivant Sciences Ltd. (NASDAQ:ROIV) as of Q1 2022.